Actinium Pharmaceuticals, Inc. Announces Exercise Of Greenshoe Option
Published: Jul 11, 2014
NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that the underwriters of the previously announced offering of 1,670,000 common shares of Actinium exercised their over-allotment option to purchase an additional 157,123 shares from the Company for $7.50 per share. The public offering previously closed on June 30, 2014.
Help employers find you! Check out all the jobs and post your resume.